US 11,999,999 B2
Synthesis of novel disulfide linker based nucleotides as reversible terminators for DNA sequencing by synthesis
Jingyue Ju, Englewood Cliffs, NJ (US); Xiaoxu Li, New York, NY (US); Xin Chen, New York, NY (US); Zengmin Li, Flushing, NY (US); Shiv Kumar, Belle Meade, NJ (US); Shundi Shi, Ozone Park, NY (US); Cheng Guo, Brooklyn, NY (US); Jianyi Ren, New York, NY (US); Min-Kang Hsieh, New York, NY (US); Minchen Chien, Tenafly, NJ (US); Chuanjuan Tao, Fort Lee, NJ (US); Ece Erturk, New York, NY (US); Sergey Kalachikov, Bronx, NY (US); and James J. Russo, New York, NY (US)
Assigned to THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, New York, NY (US)
Filed by Jingyue Ju, Englewood Cliffs, NJ (US); Xiaoxu Li, New York, NY (US); Xin Chen, New York, NY (US); Zengmin Li, Flushing, NY (US); Shiv Kumar, Belle Meade, NJ (US); Shundi Shi, Ozone Park, NY (US); Cheng Guo, Brooklyn, NY (US); Jianyi Ren, New York, NY (US); Min-Kang Hsieh, New York, NY (US); Minchen Chien, Tenafly, NJ (US); Chuanjuan Tao, Fort Lee, NJ (US); Ece Erturk, New York, NY (US); Sergey Kalachikov, Bronx, NY (US); and James J. Russo, New York, NY (US)
Filed on Jul. 12, 2021, as Appl. No. 17/373,295.
Application 17/373,295 is a continuation of application No. 15/763,364, granted, now 11,085,076, previously published as PCT/US2016/054236, filed on Sep. 28, 2016.
Claims priority of provisional application 62/257,102, filed on Nov. 18, 2015.
Claims priority of provisional application 62/233,950, filed on Sep. 28, 2015.
Prior Publication US 2022/0411860 A1, Dec. 29, 2022
Int. Cl. C12Q 1/68 (2018.01); C07H 19/10 (2006.01); C07H 19/14 (2006.01); C07H 19/20 (2006.01); C12Q 1/6869 (2018.01)
CPC C12Q 1/6869 (2013.01) [C07H 19/10 (2013.01); C07H 19/14 (2013.01); C07H 19/20 (2013.01)] 21 Claims
 
1. A compound of the formula:

OG Complex Work Unit Chemistry
Wherein
B is a base;
L1 is covalent linker;
L2 is covalent linker;
R3 is —OH, monophosphate, polyphosphate or a nucleic acid;
R4A is hydrogen, —CH3, —CX13, —CHX12, —CH2X1, —CN, —Ph, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4B is hydrogen, —CH3, —CX23, —CHX22, —CH2X2, —CN, —Ph, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R5 is a detectable label or anchor moiety;
R6 is hydrogen or a polymerase-compatible cleavable moiety and the polymerase-compatible cleavable moiety is —CH2—CH═CH2, —CH2N3 or

OG Complex Work Unit Chemistry
R8A is hydrogen;
R8B is hydrogen;
R9, R10, and R11 are each independently hydrogen or unsubstituted alkyl;
R7 is hydrogen or —OR7A, wherein R7A is hydrogen; and
X1 and X2 are independently halogen.